New Pancreatic Cancer Drug Offers Hope in Clinical Trial

Despite advances across the board in cancer treatments, pancreatic cancer has remained one of the most daunting challenges facing patients and their doctors. That could be changing, thanks to a promising new drug that just completed an important clinical trial.

This drug could herald a new treatment era. It has been shown to significantly extend the lives of pancreatic cancer patients when compared with traditional chemotherapy treatments.

Pancreatic cancer is one of the more rare cancers, representing about 3 percent of new cancer cases each year in the U.S. But since the disease is so difficult to treat, it is responsible for more than 8 percent of cancer deaths – the third-leading cause of cancer-related deaths in the U.S. It is expected to claim more than 52,000 lives in 2026.

Clinical Trial Results: How Daraxonrasib Improves Survival Rates

The recent clinical trial involved 500 patients with advanced, metastatic, pancreatic cancer who have stopped responding to previous treatment. Patients received either the pill, called Daraxonrasib, or additional chemotherapy.

Key Benefits of Daraxonrasib vs. Chemotherapy

·      Tumor control. The pill kept tumors under control twice as long as chemotherapy. Those taking the experimental pill lived for a median of more than 13 months, compared with less than seven months for patients on chemotherapy.

·      Patient quality of life. The pill also proved superior to chemotherapy in terms of how it affected patients’ overall health, creating fewer negative side effects.

It remains to be seen how the drug works against newly diagnosed cancers or cancers in earlier stages of development. The drug could also be used in combination with other treatments to provide better outcomes.

What is certain is that this is great news for thousands of patients and their families who have been anxiously awaiting a new treatment for this stubborn cancer. This is a new opportunity and hopefully the inauguration of a new era with more effective treatments and better results.

The drug is still working its way through the FDA approvals process. But the regulator has granted the drug’s maker a “safe to proceed” letter, allowing expanded access to the experimental treatment for patients with previously treated metastatic pancreatic cancer. This allows doctors to apply for treatment on behalf of eligible patients.

Why Is Pancreatic Cancer So Difficult To Treat?

Traditionally, most pancreatic cancers are treated with chemotherapy. In some instances,  surgery and radiation therapy are used. The disease has a five-year survival rate of less than 14 percent.

There are two significant challenges in treating pancreatic cancer. The first is the biology of the tumor itself, with early tumor spread that doesn’t tend to trigger the body’s immune response and has a genetic makeup with few targetable vulnerabilities.

Further, the disease often grows undetected until it reaches advanced stages. Consider that this small organ (shaped like a flat six-inch pear) is located deep inside your body, in the back of the abdomen. Often, by the time pancreatic cancer causes symptoms, the tumor involves surrounding blood vessels or the cancer spreads to other parts of the body.

Symptoms and Detection Challenges

When there are symptoms, they include:

·      Pain in your abdomen that spreads to your sides or back

·      Loss of appetite

·      Unexplained weight loss

·      Jaundice (yellowing) of your skin or whites of your eyes

·      Dark-colored urine

·      A recent diagnosis of diabetes that is difficult to control

·      Unexplained fatigue

·      Pain and swelling in an arm or leg

Researchers have had great success developing screening tests for breast, colon and lung cancer, but we lack an early-warning system for pancreatic cancer. Only a small minority of pancreatic cancers have well-established genetic risk factors.

This content is not AI generated.